Article Information
History
- November 14, 2024.
Article Versions
- Version 1 (October 28, 2024 - 15:43).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Marta Milà-Alomà1,2,
- Duygu Tosun1,2,*,
- Suzanne E. Schindler3,
- Zachary Hausle1,2,
- Yan Li3,
- Kellen K. Petersen3,
- Jeffrey L. Dage4,5,
- Lei Du-Cuny6,
- Ziad S. Saad7,
- Benjamin Saef3,
- Gallen Triana-Baltzer7,
- David L. Raunig8,
- Janaky Coomaraswamy8,
- Michael Baratta8,
- Emily A. Meyers9,
- Yulia Mordashova6,
- Carrie E. Rubel10,
- Kyle Ferber10,
- Hartmuth Kolb11,
- Nicholas J. Ashton12,
- Henrik Zetterberg12,13,14,15,16,17,
- Erin G. Rosenbaugh18,
- Martin Sabandal18,
- Leslie M. Shaw19,
- Anthony W. Bannon20,
- William Z. Potter21,
- Alzheimer’s Disease Neuroimaging Initiative (ADNI)**,
- Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease Project Team
- 1Northern California Institute for Research and Education, San Francisco, CA, USA 94141
- 2Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA 94143
- 3Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA 63110
- 4Department of Neurology, Indiana University School of Medicine, 355 W 16th St Indianapolis, IN, USA 46202
- 5Stark Neurosciences Research Institute, Indiana University School of Medicine, NB Building, 320 W 15th St #414, Indianapolis, IN, USA 46202
- 6AbbVie, Knollstraße 50, 67061, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany
- 7Neuroscience Biomarkers, Johnson and Johnson Innovative Medicine, 3210 Merryfield Row, San Diego, CA, USA 20892
- 8Takeda Pharmaceutical Company Ltd., 500 Kendall St., Cambridge, MA, USA 02142
- 9Alzheimer’s Association, 225 N Michigan Ave., Chicago, IL, USA 60603
- 10Biogen, 225 Binney St., Cambridge, MA, USA 02142
- 11Enigma Biomedical Group, CA, USA
- 12Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Biskopsbogatan 27, S-431 80, Mölndal, Sweden
- 13Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Biskopsbogatan 27, S-431 80, Mölndal, Sweden
- 14UK Dementia Research Institute Fluid Biomarkers Laboratory, UK DRI at UCL, 3rd Floor, Queen Square House, Queen Square, London WC1N 3BG, United Kingdom
- 15Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom
- 16Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Units 1501-1502, 1512-1518, 15/F Building 17W, 17 Science Park W Ave, Science Park, Hong Kong, China
- 17Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, 600 Highland Ave J5/1Mezzanine, Madison, WI, USA 53792
- 18The Foundation for the National Institutes of Health, 11400 Rockville Pike, Suite 600, North Bethesda, MD, USA 20852
- 19Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce St., Philadelphia, PA, USA 19104
- 20AbbVie, 1400 Sheridan Rd., North Chicago, IL, USA 60064
- 21Highly qualified expert
- ↵*Correspondence to: Duygu Tosun, PhD Full address: Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA. E-mail duygu.tosun{at}ucsf.edu
Posted November 14, 2024.
Timing of changes in Alzheimer’s disease plasma biomarkers as assessed by amyloid and tau PET clocks
